sucroferric oxyhydroxide sold brand name velphoro noncalcium ironbased phosphate binder used control serum phosphorus levels adults chronic kidney disease ckd haemodialysis hd peritoneal dialysis used form chewable sucroferric oxyhydroxide also known mixture polynuclear ironiiioxyhydroxide sucrose common side effects include diarrhea discolored feces may become less frequent continued approved medical use united states november european union august sucroferric oxyhydroxide approved us food drug administration fda european medicines agency ema control serum phosphorus levels patients chronic kidney disease ckd frequently reported adverse drug reactions reported trials diarrhoea discoloured vast majority gastrointestinal adverse events occurred early treatment abated time continued druginteraction studies post hoc analyses phase iii studies showed clinically relevant interaction sucroferric oxyhydroxide systemic exposures losartan furosemide omeprazole digoxin lipidlowering effects oral vitamin receptor according european label summary product characteristics medicinal products known interact iron eg doxycycline potential interact velphoro administered least one hour two hours allows sucroferric oxyhydroxide bind phosphate intended excreted without coming contact medications gut might interact according us prescribing information velphoro prescribed oral combination sucroferric oxyhydroxide levothyroxine contraindicated sucroferric oxyhydroxide contains iron may cause levothyroxine become insoluble gut thereby preventing intestinal absorption healthy person normal serum phosphate levels maintained regulation dietary absorption bone formation resorption equilibration intracellular stores renal kidney function impaired phosphate excretion declines without specific treatment hyperphosphataemia occurs almost universally despite dietary phosphate restriction conventional dialysis patients dialysis hyperphosphataemia independent risk factor fractures cardiovascular disease abnormalities phosphate metabolism hyperphosphatemia included definition new chronic kidney bone disorder sucroferric oxyhydroxide comprises polynuclear ironiiioxyhydroxide core stabilised carbohydrate shell composed sucrose carbohydrate shell stabilises ironiiioxyhydroxide core preserve phosphate adsorption capacity dietary phosphate binds strongly sucroferric oxyhydroxide gastrointestinal gi tract bound phosphate eliminated faeces thereby prevented absorption blood consequence decreased dietary phosphate absorption serum phosphorus concentrations reduced chewability sucroferric oxyhydroxide compares well calcimagon calcium containing tablet used standard good tablets sucroferric oxyhydroxide easily disintegrated artificial saliva clinical phase iii studies showed sucroferric oxyhydroxide achieves maintains phosphate levels compliance kdoqi reduction serum phosphate levels sucroferric oxyhydroxidetreated patients noninferior sevelamertreated patients required daily pill burden lower sucroferric sucroferric oxyhydroxide binds phosphate empty full stomach conditions across physiologically relevant ph range gi retrospective realworld study hyperphosphatemic peritoneal dialysis patients prescribed switch sucroferric oxyhydroxide sevelamer lanthanum carbonate calcium acetate significant reductions serum phosphorus levels along decrease prescribed daily pill httpsenwikipediaorgwikisucroferricoxyhydroxide